Strattera

Strattera

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

Zuellig
Concise Prescribing Info
Contents
Atomoxetine HCl
Indications/Uses
ADHD in childn ≥6 yr, adolescent & adult as part of comprehensive treatment program.
Dosage/Direction for Use
Adult Initially 40 mg, maintained for min of 7 days prior to upward dose titration. Maintenance daily dose: 80 mg-100 mg. Max: 100 mg. Childn >70 kg Initially 40 mg, maintained for min of 7 days prior to upward dose titration. Maintenance: 80 mg. Max: 100 mg. Up to 70 kg 0.5 mg/kg, maintained for a min of 7 days prior to upward dose titration. Maintenance daily dose: 1.2 mg/kg/day.
Administration
May be taken with or without food: Swallow whole, do not open cap.
Contraindications
Hypersensitivity. Concomitant use w/ MAOIs (w/in min of 2 wk after discontinuing therapy & vice versa). Narrow-angle glaucoma. Severe CV or cerebrovascular disorders. Pheochromocytoma or history of pheochromocytoma.
Special Precautions
Suicide attempts & suicidal ideation. Sudden death & preexisting cardiac abnormalities. Increase in heart rate (mean <10 bpm) &/or increase in BP (mean <5 mmHg). Patients w/ additional risk factors for cerebrovascular conditions (eg, history of CV disease, concomitant medications that elevate BP). Discontinue in patients w/ jaundice or lab evidence of liver injury. Possibility of exacerbation of preexisting psychotic or manic symptoms. Monitor for the appearance or worsening of aggressive behavior, hostility or emotional lability. Possible allergic events. Seizures. Monitor growth & development in childn & adolescent. Monitor appearance or worsening of anxiety symptoms, depressed mood & depression or tics. Not for the treatment of major depressive episodes &/or anxiety. May affect ability to drive & use machines. Pregnancy & lactation. Childn <6 yr.
Adverse Reactions
Childn: Decreased appetite; headache, somnolence; abdominal pain, vomiting, nausea; increased BP & heart rate. Anorexia (loss of appetite); irritability, mood swings, insomnia, agitation, anxiety, depression & depressed mood, tics; dizziness; mydriasis; constipation, dyspepsia; dermatitis, pruritus, rash; fatigue, lethargy, chest pain; decreased wt. Adult: Decreased appetite; insomnia; headache; dry mouth, nausea; increased BP & heart rate. Agitation, decreased libido, sleep disorder, depression & depressed mood, anxiety; dizziness, dysgeusia, paresthesia, somnolence (including sedation), tremor; palpitations, tachycardia; flushing, hot flush; abdominal pain, constipation, dyspepsia, flatulence, vomiting; dermatitis, hyperhidrosis, rash; dysuria, pollakiuria, urinary hesitation/retention; dysmenorrhea, ejaculation disorder, erectile dysfunction, prostatitis, male genital pain; asthenia, fatigue, lethargy, chills, feeling jittery, irritability, thirst.
Drug Interactions
Increased exposure w/ CYP2D6 inhibitors eg, SSRIs (eg, fluoxetine, paroxetine), quinidine, terbinafine. Potentiated CV effects w/ high dose salbutamol (or other β2 agonists). Increased risk of QT interval prolongation w/ other QT prolonging drugs (eg, neuroleptics, class IA & III anti-arrhythmics, moxifloxacin, erythromycin, methadone, mefloquine, TCAs, lithium or cisapride), drugs that cause electrolyte imbalance (eg, thiazide diuretics) & CYP2D6 inhibitors. Potential risk of seizures w/ medicinal drugs known to lower seizure threshold (eg, TCAs or SSRIs, neuroleptics, phenothiazines or butyrophenone, mefloquine, chloroquine, bupropion or tramadol). Potential w/drawal seizures w/ benzodiazepines. May decrease the effectiveness of antihypertensive drugs. Possible increase in effects on BP w/ pressor agents or drugs that increase BP (eg, salbutamol). Potential for additive or synergistic pharmacological effects w/ drugs that affect noradrenaline including antidepressants eg, imipramine, venlafaxine & mirtazapine, or decongestants (pseudoephedrine or phenylephrine).
MIMS Class
Other CNS Drugs & Agents for ADHD
ATC Classification
N06BA09 - atomoxetine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Presentation/Packing
Form
Strattera cap 10 mg
Packing/Price
7's
Form
Strattera cap 18 mg
Packing/Price
7's
Form
Strattera cap 25 mg
Packing/Price
7's
Form
Strattera cap 40 mg
Packing/Price
7's
Form
Strattera cap 60 mg
Packing/Price
7's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in